Client of a consultant lobbyist
Vimy Pharmaceuticals Inc.
- Meetings this Parliament
- 15
- With MPs
- 2
- Since Nov 2021
- 15
- Active registrations
- 0
Most recent reported meeting: Jul 23, 2026.
Lobbying by Vimy Pharmaceuticals Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Vimy Pharmaceuticals Inc. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Jessica Cardill · Consultant
- Jason Smedvik · Special Assistant, House of Commons
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Arielle Kayabaga · Member of Parliament
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Helena Jaczek · Member of Parliament
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Matthew O'Connell · Deputy Director Financial Sector Policy, Finance Canada (FIN)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
- Shannon Ablett · Stakeholder Relations Manager, Privy Council Office (PCO)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Jade Mallette · Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Rebekah Cassidy · Special Assistant - Ontario, Health Canada (HC)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Dan Lussier · Director of Policy, Prairies Economic Development Canada (PrairiesCan)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
-
Reported by Jessica Cardill · Consultant
- Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
Communicating with government officials regarding regulatory requirements for the domestic manufacturing and market entry of generic semaglutide in Canada.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.